Sort   by:  
 Page size 
TranscriptomicsExpression data of the human hepatoblastoma cell line HepG2 treated with TGF-beta
Smad2/3 are transcription factors that engage in TGF-beta-induced transcription. We determined and analyzed HepG2 and Hep3B-specific Smad2/3 binding sites by ChIP-chip. We used expression microarrays to compare the Smad2/3 and HNF4alpha binding sites identified by ChIP-chip or ChIP-seq, respectively...
ORGANISM(S): Homo sapiens 
2011-06-08 | E-GEOD-28590 | biostudies-arrayexpress
GenomicsHNF4A-binding sites in HepG2 hepatoblastoma cells treated with TGF-beta
Specific regulation of target genes by transforming growth factor-β (TGF-β) in a given cellular context is determined in part by transcription factors and cofactors that interact with the Smad complex. In the present study, we determined Smad2 and Smad3 (Smad2/3) binding regions in the promoters of ...
ORGANISM(S): Homo sapiens 
2011-06-08 | E-GEOD-28845 | biostudies-arrayexpress
UnknownRNAi-Mediated Down-Regulation of Dicer-Like 2 and 4 Changes the Response of 'Moneymaker' Tomato to Potato Spindle Tuber Viroid Infection from Tolerance to Lethal Systemic Necrosis, Accompanied by Up-Regulation of miR398, 398a-3p and Production of Excessive Amount of Reactive Oxygen Species.
Not available
S-EPMC6521110 | biostudies-literature
UnknownThe iodide transporter Slc26a7 impacts thyroid function more strongly than Slc26a4 in mice.
Not available
S-EPMC9253019 | biostudies-literature
TranscriptomicsMYBPH, a novel transcriptional target of NKX2-1/TTF-1, inhibits ROCK1 and actomyosin assembly, and reduces cell motility and tumor metastasis
Cell migration driven by actomyosin filament assembly is a critical step in tumour invasion and metastasis. Herein, we report identification of myosin binding protein H (MYBPH) as a transcriptional target of NKX2-1 (also known as TTF-1 and TITF1), a lineage-survival oncogene in lung adenocarcinoma. ...
ORGANISM(S): Homo sapiens 
2011-12-22 | E-GEOD-26721 | biostudies-arrayexpress
UnknownOncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
Not available
S-EPMC7385391 | biostudies-literature
Sort   by:  
 Page size